Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 3, Issue 3, 2012, Pages 302-308

  Kawamori, Ryuzo ^a   Kaku, Kohei ^c   Hanafusa, Toshiaki ^d   Kashiwabara, Daisuke ^e   Kageyama, Shigeru ^b   Hotta, Nigishi ^f  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHUBU ROSAI HOSPITAL   (Japan)

Author keywords

Nateglinide; Repaglinide; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BRAIN INFARCTION; COLD SWEAT; COLON ADENOMA; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RHINOPHARYNGITIS; TREATMENT RESPONSE; VOMITING;

EID: 84861985828     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00188.x     Document Type: Article

References (19)

1. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
3. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78.
6. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
7. Gromada J, Dissing S, Kofod H, et al. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-1032.
8. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
9. Hansen MK, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and repaglinide on the human β-cell sulphonylurea receptor 1. Diabetes 2002; 51: 2789-2795.
10. Repaglinide (marketed as Surepost) information [online article], Available at: (last accessed on 23 April 2011) (Japanese).
11. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
12. Kosaka K, Kikuchi M, Tarui S, et al. Late phase-II dose-ranging study of a novel hypoglycemic agent, AY4166, on NIDDM in Japan: 4-armed double-blind multicenter study. Clinical Pharmacology and Therapy 1997; 7: 669-697 (Japanese).
13. Kosaka K, Kikuchi M, Tarui S, et al. Phase-III study of a novel hypoglycemic agent, AY4166, on NIDDM patients in Japan(1): alpha-glucosidase inhibitor, voglibose-controlled multicenter double blind study. Clinical Pharmacology and Therapy 1997; 7: 699-727 (Japanese).
14. Japan Diabetes Society (ed). Evidence-based Practice Guideline for the Treatment of Diabetes in Japan 2010. Nankodo, Tokyo, 2010 (Japanese).
15. Japan Diabetes Society (ed). Treatment Guide for Diabetes 2010. Bunkodo, Tokyo, 2010 (Japanese).
16. Japan Diabetes Society (ed). Treatment Guide for Diabetes 2007. Bunkodo, Tokyo, 2007.
17. Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 2001; 24: 73-77.
18. Kosaka K, Urae A, Amamoto T, et al. A Phase I study of AY4166 in healthy male volunteers -single oral administration in fasting state. Clinical Pharmacology and Therapy 1997; 7: 585-599 (Japanese).
19. Hu S, Boettcher BR, Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 2003; 46: M37-M43.